Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
Jesús F. San Miguel, M.D., Ph.D., Rudolf Schlag, M.D., Nuriet K. Khuageva, M.D., Ph.D., Meletios A. Dimopoulos, M.D., Ofer Shpilberg, M.D., Ph.D., Martin Kropff, M.D., Ivan Spicka, M.D., Ph.D., Maria T. Petrucci, M.D., Antonio Palumbo, M.D., Olga S. Samoilova, M.D., Ph.D., Anna Dmoszynska, M.D., Ph.D., Kudrat M. Abdulkadyrov, M.D., Ph.D., Rik Schots, M.D., Ph.D., Bin Jiang, M.D., Maria-Victoria Mateos, M.D., Ph.D., Kenneth C. Anderson, M.D., Dixie L. Esseltine, M.D., Kevin Liu, Ph.D., Andrew Cakana, M.D., Helgi van de Velde, M.D., Ph.D., Paul G. Richardson, M.D., for the VISTA Trial Investigators
Background The standard treatment for patients with multiplemyeloma who are not candidates for high-dose therapy is melphalanand prednisone. This phase 3 study compared the use of melphalanand prednisone with or without bortezomib in previously untreatedpatients with multiple myeloma who were ineligible for high-dosetherapy.
Methods We randomly assigned 682 patients to receive nine 6-weekcycles of melphalan (at a dose of 9 mg per square meter of body-surfacearea) and prednisone (at a dose of 60 mg per square meter) ondays 1 to 4, either alone or with bortezomib (at a dose of 1.3mg per square meter) on days 1, 4, 8, 11, 22, 25, 29, and 32during cycles 1 to 4 and on days 1, 8, 22, and 29 during cycles5 to 9. The primary end point was the time to disease progression.
Results The time to progression among patients receiving bortezomibplus melphalan–prednisone (bortezomib group) was 24.0months, as compared with 16.6 months among those receiving melphalan–prednisonealone (control group) (hazard ratio for the bortezomib group,0.48; P<0.001). The proportions of patients with a partialresponse or better were 71% in the bortezomib group and 35%in the control group; complete-response rates were 30% and 4%,respectively (P<0.001). The median duration of the responsewas 19.9 months in the bortezomib group and 13.1 months in thecontrol group. The hazard ratio for overall survival was 0.61for the bortezomib group (P=0.008). Adverse events were consistentwith established profiles of toxic events associated with bortezomiband melphalan–prednisone. Grade 3 events occurred in ahigher proportion of patients in the bortezomib group than inthe control group (53% vs. 44%, P=0.02), but there were no significantdifferences in grade 4 events (28% and 27%, respectively) ortreatment-related deaths (1% and 2%).
Conclusions Bortezomib plus melphalan–prednisone was superiorto melphalan–prednisone alone in patients with newly diagnosedmyeloma who were ineligible for high-dose therapy. (ClinicalTrials.govnumber, NCT00111319
[ClinicalTrials.gov]
.)
Source Information
The authors' affiliations are listed in the Appendix.
Address reprint requests to Dr. San Miguel at Hospital Universitario de Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain, or at sanmigiz{at}usal.es.
Bauer, K., Skoetz, N., Brillant, C., Herbst, C., Monsef, I., Kluge, S., Engert, A.
(2009). Tenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Acute Myeloid Leukemia. JNCI J Natl Cancer Inst
101: E1-E1
[Full Text]
Kager, L. M, Kersten, M.-J., Kloppenborg, R. P., Van Oers, R., Van den Born, B.-J.
(2009). Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma. BMJ Case Reports
2009: bcr0620091926-bcr0620091926
[Abstract][Full Text]
Falanga, A., Marchetti, M.
(2009). Venous Thromboembolism in the Hematologic Malignancies. JCO
27: 4848-4857
[Abstract][Full Text]
Comenzo, R. L.
(2009). How I treat amyloidosis. Blood
114: 3147-3157
[Abstract][Full Text]
Harousseau, J.-L., Attal, M., Avet-Loiseau, H.
(2009). The role of complete response in multiple myeloma. Blood
114: 3139-3146
[Abstract][Full Text]
Haynes, R. J., Read, S., Collins, G. P., Darby, S. C., Winearls, C. G.
(2009). Presentation and survival of patients with severe acute kidney injury and multiple myeloma: 20-year experience from a single centre. Nephrol Dial Transplant
0: gfp488v1-gfp488
[Abstract][Full Text]
Kettle, J. K, Finkbiner, K. L, Klenke, S. E, Baker, R. D, Henry, D. W, Williams, C. B
(2009). Initial therapy in multiple myeloma: investigating the new treatment paradigm. J Oncol Pharm Pract
15: 131-141
[Abstract]
Anguiano, A., Tuchman, S. A., Acharya, C., Salter, K., Gasparetto, C., Zhan, F., Dhodapkar, M., Nevins, J., Barlogie, B., Shaughnessy, J. D. Jr, Potti, A.
(2009). Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma. JCO
27: 4197-4203
[Abstract][Full Text]
Reece, D. E., Sanchorawala, V., Hegenbart, U., Merlini, G., Palladini, G., Fermand, J.-P., Vescio, R. A., Liu, X., Elsayed, Y. A., Cakana, A., Comenzo, R. L., for the VELCADE CAN2007 Study Group,
(2009). Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood
114: 1489-1497
[Abstract][Full Text]
Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J.-P., Lenain, P., Casassus, P., Azais, I., Decaux, O., Garderet, L., Mathiot, C., Fontan, J., Lafon, I., Virion, J. M., Moreau, P.
(2009). Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial. JCO
27: 3664-3670
[Abstract][Full Text]
Middeldorp, J., Kamphuis, W., Sluijs, J. A., Achoui, D., Leenaars, C. H. C., Feenstra, M. G. P., van Tijn, P., Fischer, D. F., Berkers, C., Ovaa, H., Quinlan, R. A., Hol, E. M.
(2009). Intermediate filament transcription in astrocytes is repressed by proteasome inhibition. FASEB J.
23: 2710-2726
[Abstract][Full Text]
Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N. C., Richardson, P. G., Carrasco, R. D., Anderson, K. C.
(2009). Bortezomib induces canonical nuclear factor-{kappa}B activation in multiple myeloma cells. Blood
114: 1046-1052
[Abstract][Full Text]
Richardson, P. G., Xie, W., Mitsiades, C., Chanan-Khan, A. A., Lonial, S., Hassoun, H., Avigan, D. E., Oaklander, A. L., Kuter, D. J., Wen, P. Y., Kesari, S., Briemberg, H. R., Schlossman, R. L., Munshi, N. C., Heffner, L. T., Doss, D., Esseltine, D.-L., Weller, E., Anderson, K. C., Amato, A. A.
(2009). Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. JCO
27: 3518-3525
[Abstract][Full Text]
Lonial, S.
(2009). Risky business in myeloma. Blood
114: 496-497
[Full Text]
Reece, D., Song, K. W., Fu, T., Roland, B., Chang, H., Horsman, D. E., Mansoor, A., Chen, C., Masih-Khan, E., Trieu, Y., Bruyere, H., Stewart, D. A., Bahlis, N. J.
(2009). Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood
114: 522-525
[Abstract][Full Text]
Kapoor, P., Kumar, S., Fonseca, R., Lacy, M. Q., Witzig, T. E., Hayman, S. R., Dispenzieri, A., Buadi, F., Bergsagel, P. L., Gertz, M. A., Dalton, R. J., Mikhael, J. R., Dingli, D., Reeder, C. B., Lust, J. A., Russell, S. J., Roy, V., Zeldenrust, S. R., Stewart, A. K., Kyle, R. A., Greipp, P. R., Rajkumar, S. V.
(2009). Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood
114: 518-521
[Abstract][Full Text]
Harousseau, J.-L., Moreau, P.
(2009). Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma. NEJM
360: 2645-2654
[Full Text]
Chanan-Khan, A. A., Sonneveld, P., Harousseau, J.-L., Richardson, P. G.
(2009). Reply to C.A. Dasanu et al. JCO
27: 2294-2296
[Full Text]
Harousseau, J.-L., Dreyling, M., On behalf of the ESMO Guidelines Working Group,
(2009). Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol
20: iv97-iv99
[Full Text]
Ocio, E. M., Maiso, P., Chen, X., Garayoa, M., Alvarez-Fernandez, S., San-Segundo, L., Vilanova, D., Lopez-Corral, L., Montero, J. C., Hernandez-Iglesias, T., de Alava, E., Galmarini, C., Aviles, P., Cuevas, C., San-Miguel, J. F., Pandiella, A.
(2009). Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood
113: 3781-3791
[Abstract][Full Text]
Ma, W. W., Adjei, A. A.
(2009). Novel Agents on the Horizon for Cancer Therapy. CA Cancer J Clin
59: 111-137
[Abstract][Full Text]
Blade, J., Rosinol, L.
(2009). Changing paradigms in the treatment of multiple myeloma. haematol
94: 163-166
[Full Text]
Richardson, P. G., Mitsiades, C., Laubach, J., Chauhan, D., Hideshima, T., Anderson, K.
(2009). Realizing the Anticancer Potential of Proteasome Inhibition: The Clinical Development of Bortezomib and Second-generation Proteasome Inhibitors. Am Soc Clin Oncol Ed Book
2009: 163-170
[Abstract][Full Text]
Reece, D., Harousseau, J.-L., Gertz, M. A.
(2009). Nontransplant Therapy of Myeloma, High-dose Therapy for Myeloma, and a Personalized Care Plan for Treatment of Myeloma. Am Soc Clin Oncol Ed Book
2009: 502-509
[Abstract][Full Text]
Islam, A., Ambrus, J. L., Avvisati, G., Tsubokura, M., Kami, M., Komatsu, T., Miguel, J. F. S., van de Velde, H., Richardson, P. G.
(2008). Bortezomib plus Melphalan and Prednisone for Multiple Myeloma. NEJM
359: 2613-2614
[Full Text]
(2008). All you need to read in the other general journals. BMJ
337: a1510-a1510
[Full Text]
Durie, B. G.M.
(2008). Treatment of Myeloma -- Are We Making Progress?. NEJM
359: 964-966
[Full Text]
(2008). Bortezomib plus Melphalan and Prednisone for Multiple Myeloma. JWatch Oncology and Hematology
2008: 1-1
[Full Text]
Previous
